A Review on Formulation of nanaoparticles: liposomal formulation

Dr. Abera Ahmed[1*], Dr. Atiya Akram[2], Dr. Fauzia Rehman[3], Dr. Zainab Hussain[4]

[1*] Lecturer Department of Pharmacy, The University of Faisalabad, Pakistan

[2] Department of Pharmacy , The University of Faisalabad, Pakistan

[3] Lecturer Department of Pharmacy, The University of Faisalabad, Pakistan

[4]Department of Pharmacy, Agriculture University Faisalabad, Pakistan

Corresponding author at: Department of Pharmacy, The University of Faisalabad, Pakistan

Contact: +923064829330, **Email**: abeeraahmed27@gmail.com

Abstract

Pharmacotherapy is the most appropriate approach for treating a disease and provide the treatment either symptomatic or definite for curing a disease. There are various routes of administration of a drug but the route which is most important and mostly used without any invasive procedure is oral route. But there are some drawbacks of this mostly used route as pre-systemic elimination of drug as well as the first pass hepatic effect of a drug. The most important feature of a drug to give its utmost benefit is its bioavailabiloity and which is also limited of some drugs given orally due to various factors affecting it like membrane permeability, pharmacokinetic features, solubility as well as the rate of dissolution. To overcome all these factors affecting the drug bioavailabulity some modifications are done to get the proper effect of drug like to increase solubility these drugs are prepared in nano formulation to provide the maximum concentration at the required site of action. One of these innovations in formulation of drugs is liposomes as to formulate the drugs in lipid based drug delivery. Liposomes are trifling synthetic vesicles which are spherical in shape that can be formed by the cholesterol in addition to natural but non-toxic phospholipids. Owed to their magnitude in addition to hydrophobic as well as hydrophilic oddity these liposomes are encouraging systems intended for drug delivery.

Keywords: drugs, bioavailability, permeability, phospholipids, hydrophilic, hydrophobic

Introduction

Oral drug delivery is the most popular route of administration that prevents extravasation of drug, thrombosis and catheter infection (Roger, Lagarce and

Benoit, 2011).Drawbacks to oral administration including poor solubility, physicochemical properties of drug, rapid metabolism, instability and low permeability that decrease oral bioavailability of drug (Prabhu, Ortega and Ma, 2005).The drugs that limits the absorption and dissolution are poorly soluble in water. This poor solubility leads to lack of dose frequency and high inter- and intra-subject variability (Porter and Charman, 2001).The oral bioavailability of drug depends upon various factors that includes first pass metabolism, permeability of drug across membrane, pharmacokinetic parameter (Absorption, distribution, metabolism, excretion), solubility and dissolution rate (H.D. *et al.*, 2013). Drugs that show poor systemic bioavailability are highly metabolized by stomach, liver or by intestinal enzymes. The major factor in the bioavailability of a drug is to administered orally, before entering into the systemic circulation is known as pre-systemic elimination and first pass metabolism (Merisko-Liversidge and Liversidge, 2008). To improve the solubility problems, various novel approaches include pH adjustment, co-solvent and surfactant, complication, micronization, microspheres and nanoparticle. Formulation plays an important role in the rate and extent of absorption of the drugs. Drugs are classified according to Biopharmaceutical Classification System (BCS). Such drugs having acceptable membrane permeability and low solubility are categorized under BCS class Ⅱ (Pouton, 2006).

Lipid-based drug delivery system

Taking interest in the lipid-based drug delivery system is relatively recent and deals with the vast majority of new chemical entities that have poor solubility and permeability to improve the delivery of existing drugs and for line extensions. To promote or inhibit the bioavailability, physico-chemical properties and physiological factors plays an important role to design the lipid-based drug. This system also considered the *in-vitro* as well as *in-vivo* condition.

Lipid-based formulation includes disperse system (suspension, emulsion or self-micro emulsifying drug delivery system (SMEDDS). These systems may then be transformed into granules, pellets, powders, and tablets. Some are incorporated directly into capsules. Some drugs listed in the lipid-based drug delivery system have gained much importance in market that includes efavirenz (Sustiva ®), saquinavir (Fortovase ®), ritonavir (Norvir ®), clofazimine (Lamprene ®) (Jannin, Musakhanian and Marchaud, 2008).An accurate selection of lipid vehicles, formulation techniques and rational delivery system design plays an important role in success of lipid-based drugs. Unfortunately, the current development techniques of lipid-based drug delivery system require a lot of *in-vivo* experiments and

consumption of more cost and time. So there is need of *in-vitro* method for the selection of lipid based drugs (Dahan and Hoffman, 2008).

Mechanisms for enhancing the absorption of lipid-based drugs

Enhanced solubilization*:* Lipids that are present in GIT stimulates bile salts, cholesterol, phospholipids, biliary and pancreatic secretions and gallbladder contractions (Fleisher *et al.*, 1999). The exogenous lipid components are subjected to enzymatic digestion. Esters are quickly hydrolyzed to form different micellar species that prevents the lipophilic drug precipitation of simultaneously administered drugs.

Stimulation of lymphatic transport*:* Bioavailability of poorly water-soluble drugs may increase also by the stimulation of lymphatic transport.

Reduced efflux activity and metabolism*:* Certain lipids and surfactants may be shown to reduce efflux transporters in the gastrointestinal tract and may also to enhance the fraction of absorbed drug. Due to the gap between CYP3A4 and P- glycoprotein, this mechanism may also reduce the intra-enterocyte metabolism.(‘Manoj M.Nerurkar’, no date).

Prolongation of gastric residence time*:* Lipid contents that are present in gastrointestinal tract can delayed the gastric emptying time therefore, gastric transit time is increased.(Van Citters and Lin, 1999). As a result, the residence time of lipophilic drugs in intestine increases simultaneously. This will improve the dissolution of drug at absorptive site and hence improves absorption.

The food containing lipid components plays an important role in absorption of lipid-based drugs, leads to increased oral bioavailability. This can be determined by the stimulation of biliary and pancreatic secretions due to high fat meal, to decrease efflux activity and metabolism, to enhance permeability of intestinal wall, and to prolongation of GIT residence time and transportation through lymphatic system. Food dependent bioavailability can be reduced by formulating the lipid-based drug that can enhance the solubility and dissolution of lipophilic drugs and promotes the formation of solubilized particles that facilitates absorption. Therefore, lipophilic drugs can be used to reduce the drug dose and increasing its oral bioavailability simultaneously.

Lipid –based formulations

Novel Formulation approaches

This approach includes the selection of excipients before formulating the lipid-based drug. Novel approaches of lipid-based drug delivery system include:

Vesicular lipid- based formulations:

Lipid vesicular system consists of liposome, proliposome, Phytosomes, transferosomes, Archeosomes, Vesosomes, noisome, Ethosomes.

Phytosomes

Phytosome is a complex between a natural product and natural phospholipids, like soy phospholipids. Such a complex is obtained by reaction of stoichiometric amounts of phospholipids and the substrate in an appropriate solvent. On the basis of spectroscopic data, it has been shown that the main phospholipids-substrate interaction is due to the formation of hydrogen bonds between the polar head of phospholipids (i.e. phosphate and ammonium groups) and the polar functionalities of the substrate. When treated with water, phytosomes assumes a micellar shape forming liposomal-like structures.

Ethosomes

Ethosomes are the trivial modification of liposome, a well well-known drug delivery service. Being soft, malleable lipid vesicles, they are used for enhanced delivery of active agents. Ethosomal systems are vesicular systems composed mainly of phospholipid, ethanol, propylene glycol and water.

Archeosomes

Archeosomes are archaebacteria lipids consisting vesicles. They are less sensitive to oxidative stress, high temperature, and alkaline pH.

Archeosomes constitute a novel family of liposomes made with one or more of the fully saturated bipolar tetra ether lipids, which exerts a higher stability in comparison with conventional lipids to several conditions such as high temperature, alkaline or acidic pH, and presence of phospholipases, bile salts and serum media.

Noisomes

Nonionic surfactant vesicles (NSVs or Noisomes) are now widely studied as an alternative to liposomes. Non-ionic surfactant vesicle results from self-assembly of hydrated surfactant monomers. Noisomes are essentially nonionic surfactant based multi or unilamellar vesicles in which an aqueous solution is entirely enclosed by a membrane resulted from the organization of surfactant macromolecules as bilayers. Ether injection, hand shaking method, sonification, reverse phase evaporation, aqueous dispersion and extrusion are various methods of preparation of noisomes.

Vesosomes

Vesosomes consists of one or more bilayers enclosing an aqueous core that contains unilamellar vesicles that function as internal compartments which contain the drug and which can vary in composition from each other. The external bilayer defines the lumen, limits emission of the vesicle contents, and

protects the vesicle contents from degradation due to lipolytic enzymes. Its unique properties enable localized drug delivery in specific parts of the body and extend the duration of drug effect.

Transferosomes

Transferosomes are a special type of liposomes, consisting of phosphatidylcholine and a surfactant which act as an edge activator. Transferosomes were developed in order to take the advantage of phospholipids vesicles as transdermal drug carrier. These self-optimized aggregates, with the ultra-flexible membrane, are able to deliver the drug reproducibly either into or through the skin, depending on the choice of administration or application, with high efficiency.

Liposomes

Liposomes were found in the mid 1960's by Bangham and associates and in this manner turned into the most widely investigated medication conveyance framework. Basically, liposomes are concentric bilayer vesicles in which as fluid volume is completely encased by a membranous lipid bilayer mostly made out of common or manufactured phospholipids. Liposomes are framed when phospholipids are hydrated. The most widely recognized regular phospholipids are phosphatidylcholine (PC). These are amphiphilic atoms in which a glycerol connects to a couple of hydrophobic acyl hydrocarbon chains with a hydrophilic polar head bunch phosphocholine. Amphiphilic nature of phospholipids and their analogs render them the capacity to frame shut concentric bilayers within the sight of water.

Liposomes are shaped when slim movies of amphiphilic nature are hydrated and piles of fluid crystalline bilayers become liquid and swell. The hydrated lipid sheets confine during disturbance and self-near structure enormous multilamellar vesicles (MLVs). Sonification is done to get little unilamellar vesicles (SUVs). Expulsion is likewise done to get huge unilamellar vesicles (LUVs).

A few techniques exist for improved stacking of medications utilizing pH inclinations and potential contrast crosswise over liposomal layers. The pH inclination is made by planning liposomes with a low pH inside the vesicles pursued by the expansion of the base to the extra liposomal medium. Gathering happens at the low pH side. So, the unprotonated type of essential medication can diffuse through the bilayer. At the low pH side, the particles are predominately protonated which brings down the grouping of medication in the unprotonated structure and in this manner advances the dispersion of more atoms at the low pH side of the bilayer. Stealth liposomal innovation is intended for the intravenous medication conveyance.

Liposomes as drug-delivery vehicles

Liposomes resemble cell membranes in their structure and composition. They are typically made from natural, biodegradable, nontoxic and nonimmunogenic lipid molecules and can encapsulate or bind a variety of drug molecules into or onto their membranes. Consequently, all these properties make them attractive candidates for use as drug-delivery vehicles, as advocated by Schneider [his patent application for liposomes as drug-delivery systems in the mid-1960s was rejected because of a pre-existing patent from IGI FarbenIndustrie (1934), which claimed that aqueous suspensions of lecithin and cholesterol can be drug carriers], Bangham, Ryman and, in particular, Gregoriadis in the early 1970s. After more than a decade of work, it turned out, however, that the physicochemical and biological properties of liposomes used at that time (e.g. leakage of drug molecules and short residence in blood) limited their utility in drug delivery and, especially, in cancer therapy. Liposome applications in drug delivery depend, and are based on, physicochemical and colloidal characteristics such as composition, size, loading efficiency and the stability of the carrier, as well as their biological interactions with the cells. There are four major interactions between liposomes and cells. Lipid exchange is a long-range interaction that involves the exchange of liposomal lipids for the lipids of various cell membranes; it depends on the mechanical stability of the bilayer and can be reduced by 'alloying' the membrane with cholesterol (which gives rise to greatly improved mechanical properties, such as an increased stretching elastic modulus, resulting in stronger membranes and reduced permeability).

The second major interaction is adsorption onto cells, which occurs when the attractive forces (electrostatic, electrodynamic, van der Waals, hydrophobic insertion, hydrogen bonding, specific 'lock-and-key' etc.) exceed the repulsive forces (electrostatic, steric, hydration, nodulation, protrusion etc.). Obviously, this depends on the surface characteristics of liposomes and can be specific or nonspecific. Adsorption onto phagocytic cells is normally followed by endocytosis or, rarely, by fusion. Endocytosis delivers the liposome and its contents into the cytoplasm indirectly via a lysosomal vacuole in which low pH and enzymes may inactivate the encapsulated agent. During fusion, however, the liposome's contents are delivered directly into the cell and the liposomal lipids merge into the plasma membrane. Therefore, a substantial effort is being undertaken to utilize this mode of drug entry. Efforts range from the incorporation of fusogenic proteins into the bilayer to the preparation of metastable bilayers and pH-sensitive polymer coatings.

As has already been mentioned, however, the presence of plasma and the consequent adsorption of plasma protein can stabilize liposomes mechanically and inactivate these liposome-degradation mechanisms. For drug delivery, liposomes can be formulated as a suspension, as an aerosol or in a semisolid

form such as a gel, cream or dry powder; in vivo, they can be administered topically or parenterally. After systemic (usually intravenous) administration, which seems to be the most promising route for this carrier system, liposomes are typically recognized as foreign particles and consequently endocytosed by cells of the mononuclear phagocytic system (MPS), mostly fixed Kupffer cells in the liver and spleen. This fate is very useful for delivering drugs to these cells but, in general, excludes other applications, including site-specific drug delivery by using ligands expressed on the liposome surface in order to bind to receptors (over)expressed on the diseased cells. For this reason, a search for liposomes that could evade rapid uptake by the MPS started and a few lipid compositions that prolonged liposome blood circulation times were discovered49,50, culminating in the development of PEG-coated, sterically stabilized liposomes. Based on the liposome properties introduced above, several modes of drug delivery can be envisaged: the major ones are enhanced drug solubilization (e.g. amphotericin B, minoxidil), protection of sensitive drug molecules (e.g. cytosine arabinose, DNA, RNA, antisense oligonucleotides, ribozymes), enhanced intracellular uptake (all agents, including antineoplastic agents, antibiotics and antivirals) and altered pharmacokinetics and bio distribution of the encapsulated drug.

The latter accounts for the decreased toxicity of liposomal formulations because liposome-associated drug molecules cannot normally spill to organs such as the heart, brain and kidneys. However, we must be aware that, in some cases, liposomes can be used only as a suspending vehicle and not as a drug carrier. Examples include Taxol, cyclosporin B, prostaglandins and some low molecular weight non-steroid anti-inflammatory drugs. Often, such molecules are neither hydrophilic nor hydrophobic and, if they can be suspended, tend to stick to the surface of liposomes. Obviously, upon parenteral administration, the drug is washed away in seconds and its pharmacokinetics and bio distribution resemble formulations that solubilize the drug (such as water, 400PEG, Cremophor or tetra glycol solutions of the drug).

Applications of liposomes:

Liposomes take after cell layers in their structure and association. They are ordinarily created utilizing customary, biodegradable, nontoxic and nonimmunogenic lipids and can epitomize or tie a collection of medicine particles into or onto their movies. Thusly, all of these properties make them charming contender for use as prescription movement vehicles, as maintained by Schneider [his patent application for liposomes as medicine transport systems in the mid-1960s was rejected in perspective on a past patent from IGI FarbenIndustrie (1934), which affirmed that liquid suspensions of lecithin and cholesterol can be

sedate carriers], Bangham, Ryman and, explicitly, Gregoriadis in the mid-1970s. After over a period of work, it turned out, in any case, that the physicochemical and common properties of liposomes used around at that point (for instance spillage of medicine iotas and short living plan in blood) confined their utility in sedate movement and, especially, in dangerous development therapy. Liposome applications in quiet movement depend, and rely upon, physicochemical and colloidal characteristics, for instance, association, size, stacking efficiency and the quality of the conveyor, similarly as their common associations with the cells.

There are four critical associations among liposomes and cells. Lipid exchange is a long-broaden participation that incorporates the exchanging of liposomal lipids for the lipids of various cell layers; it depends upon the mechanical consistent quality of the bilayer and can be lessened by 'alloying' the film with cholesterol (which offers rise to fundamentally improved mechanical properties, for instance, an extended expanding adaptable modulus, achieving more grounded layers and decreased vulnerability). The second critical collaboration is adsorption onto cells, which happens when the engaging forces (electrostatic, electrodynamic, van der Waals, hydrophobic consideration, hydrogen holding, unequivocal 'lock-and-key, etc.) outperform the shocking forces (electrostatic, steric, hydration, nodulation, projection, etc.). Obviously, this depends upon the surface characteristics of liposomes and can be unequivocal or obscure. Adsorption onto phagocytic cells is commonly trailed by endocytosis or, sometimes, by mix. Endocytosis passes on the liposome and its substance into the cytoplasm in an indirect manner by methods for a lysosomal vacuole in which low pH and mixes may inactivate the exemplified master. During blend, in any case, the liposome's substance is passed on authentically into the telephone and the liposomal lipids join into the plasma film. Therefore, an impressive effort is being endeavored to utilize this strategy for drug entry. Tries stretch out from the breaker of fusogenic proteins into the bilayer to the arranging of metastable bilayers and pH-fragile polymer coatings. As has quite recently been referenced, in any case, the closeness of plasma and the following adsorption of plasma protein can settle liposomes exactly and inactivate these liposome-degradation instruments.

For cure movement, liposomes can be figured as a suspension, as a disintegrated or in a (semi)solid structure, for instance, a gel, cream or dry powder; in vivo, they can be managed topically or parenterally. After essential (typically intravenous) association, which is apparently the most reassuring course for this carrier system, liposomes are conventionally seen as outside particles and along these lines endocytosed by cells of the mononuclear phagocytic structure (MPS), by and large fixed Kupffer cells in the liver and spleen16,46. This fate is especially useful for

passing on prescriptions to these cells in any case, generally speaking, rejects various applications, including site-express medicine movement by using ligands imparted on the liposome surface in order to bind to receptors (over)expressed on the undesirable cells1. Along these lines, a journey for liposomes that could avoid quick take-up by the MPS started and a few lipid pieces that drawn out liposome blood course times were discovered, ending up at ground zero in the headway of PEG-secured, sterically offset liposomes.

Based on the liposome properties exhibited more than, a couple of strategies for drug transport can be envisioned: the noteworthy ones are overhauled calm solubilization (for instance amphotericin B, minoxidil), confirmation of delicate prescription particles (for instance cytosine arabinose, DNA, RNA, antisense oligonucleotides, ribozymes), updated intracellular take-up (all administrators, including antineoplastic authorities, hostile to contamination specialists and antivirals) and balanced pharmacokinetics and bio distribution of the encapsulated medicine. The last records for the reduced noxious nature of liposomal plans since liposome-related prescription particles can't consistently spill to organs, for instance, the heart, cerebrum and kidneys. Nevertheless, we should realize that, now and again, liposomes can be used interestingly as a suspending vehicle and not as a prescription transporter. Models fuse Taxol, cyclosporin B, prostaglandins and some low nuclear weight non-steroid relieving drugs. Routinely, such particles are neither hydrophilic nor hydrophobic and, in case they can be suspended, will all in all hold fast to the outside of liposomes. Plainly, upon parenteral association, the prescription is washed away instantly and its pharmacokinetics and bio distribution look like subtleties that solubilize the medicine, (for instance, water, 400PEG, Cremophor or tetra glycol courses of action of the drug).

Treatment Options for Metastatic Breast Cancer

The objectives for treating metastatic bosom malignancy are to broaden endurance, improve side effects, and keep up or improve in general personal satisfaction. Chemotherapeutic specialists normally utilized as first-line operators in metastatic bosom malignancy incorporate anthracyclines (i.e., doxorubicin, epirubicin), taxanes, cyclophosphamide, fluorouracil, methotrexate, vinorelbine, and capecitabine. Announced target reaction rates for these medications go from 25% to 55% in patients who have gotten no earlier chemotherapy in the metastatic setting. Patients with hormone receptor-positive tumors and constrained to direct sickness for the most part ought to likewise get hormonal treatment for metastatic infection, because of the set-up adequacy and restricted harmfulness related with these specialists. In premenopausal ladies, tamoxifen alone or in blend with a

luteinizing hormone-discharging hormone agonist is the hormonal operator of decision (Klijn et al., 2000).

In postmenopausal ladies, the consequences of a few late preliminaries recommend prevalent adequacy with aromatase inhibitors versus tamoxifen in ladies with metastatic bosom disease. (Placeholder1) (endnote) (endnote) {Wigler, 2002 #8} Moreover, aromatase inhibitors (exemestane, letrozole, and anastrozole) have demonstrated prevalent outcomes versus megestrol acetic acid derivation in patients with metastatic bosom malignancy that advanced on adjuvant or metastatic tamoxifen treatment (Kaufmann et al., 2000).

Conventional Treatment of Breast Cancer

Regular doxorubicin is viewed as one of the most dynamic specialists for the treatment of cutting-edge bosom disease; be that as it may, the advantages of traditional doxorubicin as far as antitumor action are restricted by its danger profile. Cardiovascular poisonous quality is the significant portion constraining harmfulness related with ordinary doxorubicin, confining the prescribed combined lifetime portion to 450-550 mg/m (O'Shaughnessy, 2003).

Pegylated liposomal doxorubicin has likewise indicated viability in the neoadjuvant setting in patients with privately propelled bosom disease. Pegylated liposomal doxorubicin furnishes an improved remedial record contrasted and that of ordinary doxorubicin, with a fundamentally diminished danger of cardiovascular poisonous quality and diminished myelosuppression, sickness and spewing, and alopecia {Wigler, 2002}. Also, cardiac prevention is kept up in patients with earlier customary anthracycline introduction.

These advantages may be made PLD a reasonable operator for thought in the old or in patients with previous heart ailment. Pegylated liposomal doxorubicin may likewise have clinical utility in patients with anthracycline-delicate bosom disease who arrive at the greatest lifetime total portion of ordinary doxorubicin in the adjuvant setting and can't proceed with treatment because of cardiac lethality concerns.

Antagonistic occasions related with PLD, in particular HFS and mucositis, are timetable and portion related and regularly don't prompt cessation of treatment. These occasions can be effectively overseen portion. The good wellbeing profile of PLD joined with its helpful once-month to month dosing timetable may likewise convert into an improved personal satisfaction for patients with bosom disease, in light of its constructive outcomes on personal satisfaction in patients with ovarian malignant growth {Gordon, 2001}. Pegylated liposomal doxorubicin, the most

broadly contemplated liposomal doxorubicin plan in bosom malignant growth, has been assessed in excess of 20 clinical preliminaries. In light of the clinical proof explored, apparently PLD is a reasonable helpful alternative as a bleeding edge operator in patients with metastatic bosom malignant growth. Little investigations likewise recommend a job for PLD in the neoadjuvant setting in patients with privately propelled bosom malignant growth. Further assessment of PLD in the adjuvant setting, particularly in older patients and in patients with cardiovascular illness, may likewise be justified dependent on its viability and security in patients with privately progressed and metastatic bosom malignancy (O'Shaughnessy, 2003).

It is restoratively alluring to viably convey ceramide, an antimitogenic and proapoptotic lipid second errand person, to changed cell types. Be that as it may, the focused-on conveyance of cell porous ceramide analogs, including C6-ceramide, to cells might be hindered by the hydrophobicity of these bioactive lipids, bringing about diminished adequacy. The target of this examination is to create and upgrade liposomal vehicles to enlarge ceramide conveyance to a bosom adenocarcinoma cell line. We structured traditional, cationic, and pegylated sedate discharge vesicles to usefully convey ceramide to MDA-MB-231 bosom adenocarcinoma cells. In vitro pharmacokinetic investigation showed that liposomal ceramide conveyance brought about essentially more noteworthy gathering of ceramide in MDA-MB-231 cells. Ceramide-detailed liposomes altogether restrained MDAMB-231 cell multiplication as contrasted and nonliposomal organization of ceramide. Ceramide-instigated apoptosis related with the pharmacokinetic profile and the lessened expansion in this exceptionally forceful, metastatic cell line. Liposomal ceramide definitions hindered phosphorylated Akt levels and animated caspase-3/7 action more adequately than no liposomal ceramide, occasions steady with apoptosis. Together, these outcomes demonstrate that bioactive ceramide analogs can be consolidated into traditional, cationic, or pegylated liposomal vehicles for improved medication conveyance and discharge (Stover and Kester, 2003).

Regardless of critical research here, metastatic bosom malignant growth stays an infection with a poor guess. Until a successful treatment is created, it is basic that new treatment modalities be examined. In this report, we depict a compelling strategy for conveyance of a novel snake venom disintegrin, contortrostatin (CN), in an orthotopic, xenograft model of human mammary malignancy in immunodeficient mice. CN (Mr 13,500) is a homodimeric disintegrin segregated from venom of the Southern Copperhead snake. The homodimer has two Arg-Gly-

Asp destinations, which regulate its association with integrins on tumor cells and angiogenic vascular endothelial cells. In spite of the fact that our research center has recently depicted the antitumor movement of CN in a mouse model of human mammary disease, the technique for conveyance, day by day intratumor infusion, was not translatable to clinical application.

We presently portray a clinically important technique for overseeing CN, liposomal conveyance (LCN). A novel liposomal framework has been intended for IV organization of an organically dynamic protein with full maintenance of natural action. Pharmacokinetics, bio distribution, platelet reactivity, and immunogenicity of LCN were resolved and contrasted and comparable attributes of local, unencapsulated CN. There are a few focal points to liposomal conveyance of CN: (1) LCN has an altogether drawn out circulatory half-life contrasted and local CN; (2) LCN is inactively amassed in the tumor ;(3) LCN has no platelet reactivity; and (4) LCN isn't perceived by the invulnerable framework. At last, antiangiogenic movement is a significant segment of CN's component of antitumor activity. We have shown that IV conveyance of LCN prompts strong enemy of angiogenic movement in the orthotopic, xenograft human mammary tumor model (Swenson et al., 2004).

Angiogenesis, the development of new micro vessels, isn't fundamental for various physiological procedures yet additionally happens in numerous neurotic conditions including tumor development. Studies have demonstrated that tumor development is reliant on angiogenesis. This gives the method of reasoning to antiangiogenic treatment in malignant growth. A few angiogenesis inhibitors that restrain tumor development are currently in clinical preliminaries. Angiostatin and endostatin are two as of late announced strong endogenous angiogenesis inhibitors (O'Reilly et al., 1994).

Antiangiogenic treatment with angiostatin and endostatin in disease requires delayed organization of recombinant protein in vivo. Likewise, generation of these utilitarian polypeptides has demonstrated troublesome, maybe because of physical properties and varieties in the cleansing technique by various research facilities (Cao et al., 1998). A couple of gatherings have indicated that antiangiogenic quality treatment with viral vectors is a possibly helpful way to deal with restrain tumor development in mouse models (Goldman et al., 1998).

The liposomes complexed to plasmids encoding angiostatin or endostatin hindered angiogenesis and the development of MDA-MB-435 tumors embedded in the mammary fat stack of naked mice. plasmids communicating angiostatin (PCI-Angio) or endostatin (PCIEndo) viably diminished angiogenesis utilizing an in vivo Matrigel test. At that point explored the viability of these plasmids in

diminishing the size of tumors embedded in the mammary fat cushion of bare mice. Both PCI-Angio and PCI-Endo fundamentally diminished tumor size when infused intratumorally ($P < 0.05$). Contrasted with the untreated control gathering, the mice treated with PCI-Angio and PCI-Endo showed a decrease in tumor size of 36% and 49%, individually. What's more, IV infusions of liposomes complexed to PCI-Endo decreased tumor development naked mice by almost 40% when contrasted with either void vector (PCI) or untreated controls ($P < 0.05$). These discoveries give a premise to the further advancement of nonviral conveyance of antiangiogenic qualities (Chen et al., 1999).

The backslide of malignant growth is for the most part because of multiplication of disease foundational microorganisms which couldn't be wiped out by a standard chemotherapy. Another sort of all-trans retinoic corrosive stealth liposomes was produced for forestalling the backslide of bosom malignant growth and for treating the disease in mix with a cytotoxic specialist, vinorelbine stealth liposomes. In-vitro thinks about were performed on human bosom malignant growth MCF-7 and MDA-MB-231 cells. In-vivo assessments were performed on the recently settled backslide model with bosom malignancy immature microorganisms. Results demonstrated that the molecule size of all trans-retinoic corrosive stealth liposomes was around 80nm, and the embodiment productivity was >90%. Bosom malignancy undeveloped cells were related to CD44+/CD24 phenotype and portrayed with properties: impervious to cytotoxic operator, more grounded ability of multiplication, and more grounded capacity of separation. Inhibitory impact of all-trans retinoic corrosive stealth liposomes was stronger in malignant growth immature microorganisms than in disease cells (Li et al., 2011).

Vinorelbine stealth liposomes and parthenolide stealthy liposomes were created for giving valuable pharmacological properties and to annihilate malignant growth immature microorganisms and non-undifferentiated cells together by a blend treatment. Cytotoxicity and disease foundational microorganisms (side populations) ID were performed on human bosom malignant growth cell lines MCF-7 and MDA-231, SP cells were additionally arranged from MCF-7 cells and portrayed, inhibitory impact was assessed on the arranged SP and non-SP cells. Antitumor movement was assessed on MCF-7 xenografts in naked mice. Both Vinorelbine and parthenolide restrained the expansion in MCF-7 and MDA-MB-231 cells. When contrasted with non-SP cells, inhibitory impact of vinorelbine in the SP cells was lower while a hearty inhibitory impact was seen while applying vinorelbine in combination with parthenolide. This mix treatment may give a potential methodology to destruction of bosom malignancy by focusing on disease together with malignancy undeveloped cells (Liu et al., 2008).

The anthracyclines and taxanes are commonly viewed as the most dynamic cytotoxic specialists for the administration of metastatic bosom malignant growth. During the most recent 10 years, anthracyclines specifically have gotten all the more generally utilized in adjuvant mix chemotherapy regimens, bringing about more noteworthy utilization of taxanes as first-line treatment at the hour of sickness movement (Clarke et al., 1998). To think about the efficacy of pegylated liposomal doxorubicin (PLD) with that of a typical rescue routine (comparator) in patients with taxane-obstinate propelled bosom disease.

Following disappointment of a first-or second-line taxane-containing routine for metastatic ailment, 301 ladies were arbitrarily allocated to get PLD (50 mg/m2 at regular intervals); or comparator-vinorelbine (30 mg/m2 week by week) or mitomycin C (10 mg/m2 day 1 and like clockwork) in addition to vinblastine (5 mg/m2 day 1, day 14, day 28, and day 42) each 6 to about two months. Patients were stratified before arbitrary task dependent on number of past chemotherapy regimens for metastatic ailment and nearness of bone metastases as it were. In anthracycline-credulous patients, PFS was fairly longer with PLD, comparative with the comparator. Most habitually announced unfriendly occasions were sickness (23% to31%), heaving (17%to20%), and weakness (9%to20%) and were comparable among treatment gatherings. PLD-treated patients experienced progressively palmar-plantar erythrodysesthesia (37%; 18% evaluation 3, 1 patient evaluation 4) and stomatitis (22%; 5% grades 3/4). Neuropathy (11%), obstruction (16%), and neutropenia (14%) were increasingly normal with vinorelbine. Alopecia was low in both the PLD and vinorelbine gatherings (3% and 5%). End PLD has efficacy equivalent to that of regular rescue regimens in patients with taxane-hard-headed metastatic bosom malignant growth, in this way speaking to a valuable remedial choice (Keller et al., 2004).

The controlled medication conveyance from low-temperature-touchy liposomes (LTSLs) intervened by photothermal warming from multibranched gold nanoantenna's (MGNs) in triple-negative bosom malignant growth (TNBC) cells in vitro. The remarkable geometry of MGNs empowers the age of mellow hyperthermia (~42 °C) by changing over close infrared light to warm and effectively conveying doxorubicin (DOX) from the LTSLs in bosom malignant growth cells. We confirmed the cell take-up of MGNs by utilizing both fluorescence confocal Z-stack imaging and transmission electron microscopy (TEM) imaging. We played out a cell feasibility examine and live/dead cell fluorescence imaging of the joined remedial effects of MGNs with DOX-stacked LTSLs (DOX-LTSLs) and contrasted them and free DOX and DOX-stacked non-temperature-delicate liposomes (DOXNTSLs).

Imaging of fluorescent live/dead cell pointers and MTT examine results both exhibited significant diminishes in cell reasonability when cells were treated with the blend treatment. Due to the high stage progress temperature of NTSLs, no medication conveyance was seen from the DOX-NTSLs. Outstandingly, even at a low DOX grouping of 0.5 μg/mL, the blend treatment brought about a higher (33%) cell passing comparative with free DOX (17% cell demise). The consequences of our work exhibit that the synergistic remedial effect of photograph warm hyperthermia of MGNs with tranquilize conveyance from the LTSLs can effectively destroy forceful bosom malignant growth cells with higher efficacy than free DOX by giving a controlled light-initiated methodology and limiting off-target poisonous quality (Ou et al., 2016).

Pancreatic malignancy undifferentiated organisms are liable for protection from standard treatment, metastatic potential, and illness backslide following medicines. The present treatment for pancreatic ductal adenocarcinoma (PDAC) specially focuses on the more separated malignant growth cell populace, leaving CSCs as a cell hotspot for tumor mass arrangement and repeat. Therefore, there is a dire need to improve current treatments and create novel CSC-focused on restorative methodologies. Strategies: Hyaluronic corrosive (HA) enhanced liposomes, containing diethyldithiocarbamate-copper (Cu (DDC)2), ready to focus on the particular CSC marker CD44 receptor were set up by particle slope system and completely described.

Their antiproliferative impact was assessed on pancreatic CSCs got from PDAC cell lines or patients. To explain the system of activity of Cu (DDC) 2 liposomes, ROS level balance measure within the sight of N-acetyl-L-cysteine was performed. Results: Liposomes demonstrated high exemplification proficiency and Cryo-TEM investigation uncovered the nearness of Cu (DDC) 2 precious stones in the fluid center of liposomes. In vitro test on pancreatic CSCs got from PDAC cell lines or patients demonstrated high ROS intervened anticancer movement of HA adorned liposomes. The circle development ability of CSCs acquired from patients was radically diminished by liposomal details containing Cu (DDC)2 (Marengo et al., 2019).

As of late, the idea is developing that the decreased accomplishment of nanoparticles in clinical practice is because of the adsorption of the "biomolecular crown (BC)," which changes their natural character. Aside from protein varieties, adjustments in the human metabolome may change the BC improvement, which has ineffectively been tended to up until this point. Here, glucose is utilized as a model metabolite and how the connections between liposomes (as a model nanoparticle) and plasma proteins are impacted by ordinary and diabetic sugar

blood levels is investigated. As model liposomes, Doxoves and Onivyde are utilized that are utilized for the treatment of bosom and metastatic pancreatic malignant growth, separately. It is demonstrated that glucose affects the structure and organization of BC. The natural impacts of liposome–BC buildings are researched in MCF 7 and MDA-MB-231 bosom malignant growth cells for Doxoves and in pancreatic adenocarcinoma (PANC-1) and insulinoma (INS-1) cells for Onivyde. Within the sight of glucose, the cell poisonous quality of liposome–protein buildings and take-up by human monocytic THP1 cell line increments. These outcomes exhibit that adjustments in glucose fixation, and all the more by and large changes in the human metabolome, may assume a major job in the organic personality of liposomes and, therefore, on their in vivo physiological readouts including restorative viability (Palchetti et al., 2019).

Trastuzumab in addition to docetaxel is a pillar to treat HER2-positive bosom malignant growths. In any case, creating nanoparticles could improve the adequacy/lethality equalization of this doublet by improving medication dealing and conveyance to tumors. This task intended to build up an immunoliposome in bosom malignant growth, consolidating docetaxel epitomized in a stealth liposome engrafted with trastuzumab, and looking at its exhibitions on human bosom disease cell lines with standard blend of docetaxel in addition to trastuzumab.

A few methodologies to engraft trastuzumab to pegylated liposomes were tried. Immunoliposomes made of regular (immunizer nanoconjugate-1 [ANC-1]) and engineered lipids (ANC-2) were blended utilizing standard dainty film technique and analyzed in size, morphology, docetaxel exemplification, trastuzumab engraftment rates and security. Antiproliferative movement was tried on human bosom disease models going from practically negative (MDA-MB-231), positive (MDA-MB-453) to overexpressing (SKBR3) HER2.

At long last, cell take-up of ANC-1 was contemplated by electronic microscopy. ANC-1 indicated a more noteworthy docetaxel exemplification rate (73%±6% versus 53%±4%) and longer solidness (as long as multi week) as contrasted and ANC-2. Both ANC introduced molecule size #150 nm and demonstrated comparative or higher in vitro antiproliferative exercises than standard treatment, ANC-1 performing superior to ANC-2. The IC50s for docetaxel consolidated to free trastuzumab were 8.7±4, 2±0.7 and 6±2 nM with MDA-MB-231, MDA-MB-453 and SKBR3, individually. The IC50s for ANC-1 were 2.5±1, 1.8±0.6 and 3.4±0.8 nM and for ANC-2 were 1.8±0.3 nM, 2.8±0.8 nM and 6.8±1.8 nM with MDA-MB-231, MDA-MB-453 and SKBR3, separately. Cell take-up seemed to

rely upon HER2 articulation, the higher the articulation, the higher the take-up (Rodallec et al., 2018).

A tale folate-polydiacetylene-liposome (FPL) with both focused on tranquilize conveyance and fluorescence following was set up independent from anyone else amassing. The mimicked medication conveyance was performed in Bcap-37 bosom malignant growth cells and Hs578Bst ordinary cells in-vitro. The disguise and dissemination of FPLs in cells were displayed by fluorescence cell imaging. The outcomes show the FPLs have better focusing on productivity, low cytotoxicity and great biocompatibility (Li, An and Yan, 2015).

Another tumor-restorative bacterium-based microrobot (bacteriobot) joining a paclitaxel-stacked liposomal microcargo with tumor-focusing on Salmonella Typhimurium microorganisms. The tumor-helpful liposomal bacteriobot was developed by restricting biotin atoms showed on the external film proteins of the microorganisms and streptavidin covered on the medication stacked liposomes. To begin with, we played out a motility investigation of the bacteriobot, where the microscopic organisms activated liposomes indicated a lot higher normal speed (3.09±0.44 μm/s) than the liposomes without bacterial incitation (0.40±0.14 μm/s). Second, we played out a cytotoxicity test utilizing a bosom malignancy cell line (4T1) to check the tumor-remedial viability of the bacteriobots. The medication stacked bacteriobots (IC50=16.48±0.43 μg/ml) indicated preferred tumor-slaughtering capacity over the medication containing liposome (IC50=21.91±0.74 μg/ml). In addition, the bacteriobots demonstrated solid tumor-focusing on and slaughtering properties in a basic co-culture chamber containing ordinary cells (NIH/3T3) and malignant growth cells (4T1). These outcomes uncovered that the built bacteriobots can be utilized for dynamic tumor treatment (Nguyen et al., 2016).

Aggravation, oxidative pressure, and uncontrolled cell expansion are normal key highlights of ceaseless incendiary infections, for example, atherosclerosis and malignant growth. ω3 polyunsaturated unsaturated fats (PUFAs; otherwise called omega3 unsaturated fats or fish oil) have valuable impacts against irritation upon dietary utilization. Notwithstanding, these impacts can't be completely abused except if consumes less calories are enhanced with high groupings of fish oil supplements over extensive stretches of time. Here, a nanomedicine-based methodology is introduced for conveying compelling degrees of PUFAs to provocative cells. Nanoparticles are disguised by insusceptible cells, and subsequently can sufficiently convey bioactive lipids into these objective cells.

The ω3 FA docosahexaenoic corrosive was planned into liposomes (ω-liposomes), and assessed for mitigating impacts in various kinds of resistant cells. ω-

Liposomes firmly restrained the arrival of receptive oxygen species and responsive nitrogen species from human neutrophils and murine macrophages, and furthermore repressed the generation of the ace provocative cytokines TNFα and MCP1. In addition, ω-liposomes hindered tumor-cell multiplication when assessed in FaDu head and neck squamous carcinoma and 4T1 bosom malignant growth cells in vitro societies. We recommend that ω-liposomes are a promising nano nutraceutical detailing for intravenous conveyance of fish oil FAs, which might be useful in the treatment of incendiary issue and malignant growth (Alaarg et al., 2016).

At present, chemo and radiotherapies stay to be the standard strategies for treating triple-negative bosom malignant growth (TNBC), which is known for poor forecast and high pace of mortality. Two kinds of novel double focusing on TNBC liposomes that effectively perceive both fructose transporter GLUT5 and integrin were structured and arranged. Right off the bat, a y-molded fructose RGD-Chol ligand, where a fructose and peptide Arg-Gly-Asp (RGD) were covalently joined to cholesterol, was structured and incorporated. At that point, Fru-RGD-Lip was developed by embeddings Fru-RGD-Chol into liposomes, while Fru+RGD-Lip were acquired by embeddings both Fru-chol and RGD-Chol into liposomes. The molecule size, zeta potential, epitome effectiveness and serum dependability of the paclitaxel-stacked liposomes were described.

Conventional treatment of Lung cancer

The event of lung malignant growth is connected with tobacco smoking, principally through the age of polycyclic sweet-smelling hydrocarbons (PAHs). Raised movement of cytochrome P4501A1 (CYP1A1) assumes a significant job in the metabolic handling of PAHs and its cancer-causing nature. The present work intended to explore the job of CYP1A1 quality in PAH-intervened development and tumor advancement in vitro and utilizing an in vivo creature model. RNAi system was used to restrain the overexpression of CYP1A1 quality utilizing cationic liposomes produced utilizing a lipid film-covered proliposome microparticles.

Treatment of PAH-incited human alveolar adenocarcinoma cell line with cationic liposomes conveying CYP1A1 siRNA came about in down guideline of CYP1A1 mRNA, protein just as its enzymatic movement, activating apoptosis and restraining multicellular tumor spheroids development in vitro. Moreover, quietening of CYP1A1 quality in BALB/c naked xenografts hindered tumor development by means of down guideline of CYP1A1 articulation. Out and out,

our discoveries demonstrated that liposome-based quality conveyance innovation is a suitable and stable methodology for focusing on disease causing qualities, for example, CY1PA1. This innovation encouraged by the utilization of sugar particles covered with lipid films has exhibited capacity to create anticancer impacts that may be utilized later on for helpful mediation and treatment of lung malignant growth (Zhang et al., 2019).

β-component and cisplatin joined chemotherapy right now is one of the most significant settings accessible for lung malignancy treatment in China. It may be, the clinical result is restricted by their pharmacokinetic disadvantages. Then again, the vast majority of nanomedicines have blown-up in clinical advancement because of the immense contrasts between heterogeneous clinical tumor tissues and homogenous cell-determined xenografts. In this work, we created a β-component and cisplatin co-stacked liposomal framework to viably treat lung malignant growth. Co-stacked liposomes were progressively cytotoxic to disease cells, particularly than the blend of single-stacked liposomes, profiting by their concurrent medication disguise and discharge. Subsequently, they showed attractive remedial result in both cell-inferred and persistent determined xenografts (Cao et al., 2019).

Chemotherapy for non-small cell lung malignancy (NSCLC) still prompts inadmissible clinical visualization due to poor dynamic focusing on and tumor metastasis. The goal of this investigation was to build a sort of PFV peptide changed focused on daunorubicin and dioscin codelivery liposomes, which could improve tumor focusing on and restrain tumor cell metastasis. Directed daunorubicin and dioscin co conveyance liposomes were set up by movie scattering and the ammonium sulfate inclination technique. With the perfect physicochemical properties, directed daunorubicin and dioscin codelivery liposomes displayed improved cell take-up and demonstrated solid cytotoxicity to tumor cells. Directed daunorubicin and dioscin co conveyance liposomes may give a viable methodology to the treatment of NSCLC (Wang et al., 2019).

Curcumin is a hydrophobic, polyphenolic compound got from the rhizome of the turmeric herb. 5 It has additionally indicated critical in vitro and in vivo chemo-preventive potential for different types of malignancies including leukemia, melanoma, lymphoma, bosom disease, ovarian disease, lung disease, and bone malignant growth. In contrast to different types of disease, bone tumors and its subtypes are commonly recognized during the principal many years of life and are viewed as the most predominant essential bone danger. 5 Three-dimensional printed (3DP) tissue building frameworks are considered as a brilliant decision for bone join substitutes on account of their authority over pore geometry, network,

and science. All the more altogether, the closeness of liposomal curcumin brings about a 96% diminishing in vitro osteosarcoma cell expansion and feasibility following 11 days of highlighting, contrasted with control (Seitz et al., 2005).

Most human tumors over-express receptors for development elements and peptide hormones, which are in effect progressively contemplated as a way to specifically convey cytotoxic specialists. A model being the transferrin receptor (TfR, CD71). Here, we examined articulation levels and area of TfR in various lung epithelial cell types (i.e., bronchial and alveolar epithelial cells) by stream cytometry and confocal laser checking microscopy (CLSM). Moreover, we surveyed take-up levels and cytotoxicity of transferrin (Tf)- conjugated liposomes in vitro. TfR was seen as communicated at an essentially more elevated level in bronchial epithelial cells contrasted and their alveolar partners. Cells of dangerous starting point (i.e., A549 cell line) demonstrated a higher TfR articulation level than sound alveolar epithelial sort II cells in essential culture. CLSM uncovered TfR to be found fundamentally at the basolateral part of cells, except for cells experiencing mitotic multiplication, which likewise indicated TfR at their apical films, because of their loss of cell extremity. Higher articulation levels of TfR connected well with upgraded take-up of Tf-liposomes and expanded degrees of cytotoxicity. Liposome take-up was temperature-reliant and inhibitable by abundance free Tf. Tf-conjugated liposomes show up as great possibility for a way to deal with convey cytostatic medications to locales of lung malignant growth by inward breath (Anabousi et al., 2006).

Liposomes, phospholipids, nanosized rises with a bilayer structure, have drawn a ton of enthusiasm as pharmaceutical bearers for medications and qualities. As a rule, to upgrade the adequacy of the liposomal drugs, medicate stacked liposomes are focused to the tumors by methods for various explicit ligands, for example, monoclonal antibodies. Along these lines, this audit dissects the use of counter acting agent focused on liposomes stacked with different chemotherapeutic operators and different liposomal items being worked on at test and preclinical level. Neutralizer focused on liposomes stacked with anticancer medications show high potential for clinical applications (Torchilin, 2008).

The capacities of a medication conveyance framework to target and infiltrate tumor masses are key factors in deciding the framework's chemotherapeutic viability. Here, we investigated the utility of an enemy of carbonic anhydrase IX (against CA IX) immune response and CPP33 double ligand changed triptolide-stacked liposomes (dl-TPL-lip) to at the same time improve the tumor-explicit focusing on and increment tumor cell infiltration of TPL. Besides, pharmacokinetic considers in rodents that got TPL liposomal details by endotracheal organization

demonstrated a decreased convergence of TPL (17.3%–30.6% contrasted with free TPL) in fundamental course. After aspiratory organization in orthotopic lung tumor-bearing mice, dl-TPL-lip essentially improved TPL against disease adequacy without evident fundamental poisonous quality (Lin et al., 2018).

The present examination means to assess the viability of octa-arginine (R8)-adjusted pegylated liposomal doxorubicin (R8-PLD) for the treatment of non-little cell lung malignancy, for which the essential treatment methodology right now comprises of medical procedure and radiotherapy. Cell-infiltrating peptide R8 alteration of Doxorubicin-(Dox)- stacked liposomes was performed by post-addition of a R8-conjugated amphiphilic PEG–PE copolymer (R8-PEG–DOPE) into the liposomal lipid bilayer. The utilization of liposomes has points of interest in malignant growth treatment because of their upgraded penetrability and maintenance identified with their little size (100 nm) that permits entry through flawed tumor veins and gathering specially in the tumor. Platinum-based chemotherapy is the principal line chemotherapy for NSCLC patients. Other cytotoxic specialists, for example, docetaxel, pemetrexed, gefitinib are possibilities for second or third-line treatment. Dox, joined with platinum-based treatment or radiotherapy is presently in clinical preliminaries for privately progressed NSCLC (Biswas et al., 2013).

Site-explicit conveyance of medications and therapeutics can altogether decrease sedate lethality and increment the restorative impact. Transferrin (Tf) is one appropriate ligand to be conjugated to medicate conveyance frameworks to accomplish site-explicit focusing, because of its particular official to transferrin receptors (TfR), profoundly communicated on the surfaces of tumor cells. Stealth liposomes are powerful vehicles for medications, qualities and immunizations and can be effectively altered with proteins, antibodies, and other proper ligands, bringing about appealing details for focused medication conveyance. In this investigation , doxorubicin-stacked stealth liposomes (Tf-SL-DOX) by film scattering pursued by ammonium sulfate slope strategy was figured (Li et al., 2009).

A liposome framework adjusted with chlorotoxin (ClTx), a scorpion venom peptide recently used for focusing on cerebrum tumors, was set up. It focusing on proficiency and antimetastatic conduct against metastatic bosom malignant growth exceptionally communicated MMP-2, the receptor of ClTx, were explored. 4T1, a metastatic bosom malignancy cell line got from a murine bosom tumor, was chosen as the cell model. As results, the ClTx-changed liposomes showed explicit authoritative to 4T1 as controlled by stream cytometry and confocal imaging. The

cytotoxicity test uncovered that the ClTx alteration expanded the harmfulness contrasted and nonmodified liposomes. Likewise, the adjusted liposomes additionally displayed high in vivo focusing on effectiveness in the BALB/c mice bearing 4T1 tumors. Significantly, this framework hindered the development of metastatic tumor and anticipated the frequency of lung metastasis in mice bearing 4T1 tumors with just low fundamental lethality. The information got from the in vitro and in vivo investigations affirmed that the ClTx-changed liposomes expanded the medication conveyance to metastatic bosom malignant growths. This examination demonstrated that the ClTx-altered liposomes had focusing on capacity to metastatic bosom malignant growth notwithstanding cerebrum disease, and showed a conspicuous antimetastatic impact. By and large, it might give a promising technique to metastatic bosom disease treatment (Li et al., 2009).

Role of Liposomes in prostate malignancy

As of late, there has been extensive exertion in planning improved conveyance frameworks by including site-guided surface ligands to additionally upgrade their specific focusing on. The objective of this investigation is to design R51-focused on stealth liposomes (nanoparticles secured with poly (ethylene glycol) (PEG)) that will tie toR51-communicating LNCaP human prostate disease cells and efficiently discharge the typified burden intracellularly. For this reason, liposomes (with and without PEG2000) were functionalized with a fibronectin-mimetic peptide (PR-b) and conveyed to LNCaPs.

The measure of PEG2000 and other liposomal segments were portrayed by 1H NMR, and the measure of peptide by the bicinchoninic corrosive protein examine. Fibronectin is the common ligand for R51, and a promising plan for a fibronectinmimetic peptide incorporates both the essential restricting site (RGD) and the cooperative energy site (PHSRN) associated by a linker and reached out off a surface by a spacer. We have recently planned a peptide-amphiphile, PR-b, that utilized a hydrophobic tail, associated with the N-end of a peptide head bunch made out of a spacer, the cooperative energy site grouping, a linker emulating both the separation and hydrophobicity/hydrophilicity present in the local protein fibronectin (along these lines introducing a generally "unbiased" linker), and finally the essential restricting succession.

We have analyzed diverse liposomal details, functionalized just with PR_ b or with PR_b and PEG2000. For PR _b-focused on PEGylated liposomes, efficient cell restricting was watched for peptide convergences of 2 mol % and higher. When contrasted with GRGDSP focused on stealth liposomes, PR _ b functionalization was better than that of GRGDSP as appeared by expanded LNCaP official, disguise efficiency, just as cytotoxicity after hatching of LNCaPs with tumor

putrefaction factor-R (TNFR)- exemplified liposomes. All the more critically, PR_bisR51-specific, where the same number of integrins tie to little RGD peptides. Along these lines, the proposed PR _b-focused on conveyance framework can possibly convey a helpful payload to prostate malignant growth cells in an efficient and specific way. (Demirgöz, Garg and Kokkoli, 2008)

Bauhinia purpura agglutinin (BPA) is a notable lectin that perceives galactosyl glycoproteins and glycolipids. In the present investigation, we firstly found that BPA bound to human prostate malignancy examples however not to typical prostate ones. In this way, we looked to create BPA-PEG-modified liposomes (BPA-PEG-LP) epitomizing anticancer medications for the treatment of prostate malignant growth. We analyzed the tumor targetability of BPA-PEG-LP with human prostate disease DU145 cells, and saw that fluorescently named BPA-PEG-LP overwhelmingly connected with the cells by means of the association between liposome-surface BPA and cell-surface galactosyl atoms.

We additionally saw that BPA-PEG-LP amassed in the prostate malignant growth tissue after the IV infusion to DU145 strong disease bearing mice, and unequivocally bound to the malignancy cells. In a remedial report, DU145 strong malignancy bearing mice were I.V infused thrice with BPA-PEG-LP epitomizing doxorubicin (BPA-PEG-LPDOX, 2 mg⁄kg⁄day as the DOX measurement) or PEG-modified liposomes embodying DOX (PEGLPDOX). Accordingly, BPA-PEG-LPDOX significantly stifled the development of the DU145 malignant growth cells, while PEG-LPDOX at a similar measurement as DOX indicated minimal enemy of disease impact. The present examination proposed that BPA-PEG-LP could be a helpful medication transporter for the treatment of human prostate tumors (Ikemoto et al., 2016).

As of late, there has been extensive exertion in planning improved conveyance frameworks by including site-guided surface ligands to additionally upgrade their specific focusing on. The objective of this investigation is to design R51-focused on stealth liposomes (nanoparticles secured with poly (ethylene glycol) (PEG)) that will tie toR51-communicating LNCaP human prostate disease cells and efficiently discharge the typified burden intracellularly. For this reason, liposomes (with and without PEG2000) were functionalized with a fibronectin-mimetic peptide (PR-b) and conveyed to LNCaPs.

The measure of PEG2000 and other liposomal segments were portrayed by 1H NMR, and the measure of peptide by the bicinchoninic corrosive protein examine. Fibronectin is the common ligand for R51, and a promising plan for a fibronectinmimetic peptide incorporates both the essential restricting site (RGD) and the cooperative energy site (PHSRN) associated by a linker and reached out

off a surface by a spacer. We have recently planned a peptide-amphiphile, PR-b, that utilized a hydrophobic tail, associated with the N-end of a peptide head bunch made out of a spacer, the cooperative energy site grouping, a linker emulating both the separation and hydrophobicity/hydrophilicity present in the local protein fibronectin (along these lines introducing a generally "unbiased" linker), and finally the essential restricting succession.

We have analyzed diverse liposomal details, functionalized just with PR_ b or with PR_b and PEG2000. For PR _b-focused on PEGylated liposomes, efficient cell restricting was watched for peptide convergences of 2 mol % and higher. When contrasted with GRGDSP focused on stealth liposomes, PR _ b functionalization was better than that of GRGDSP as appeared by expanded LNCaP official, disguise efficiency, just as cytotoxicity after hatching of LNCaPs with tumor putrefaction factor-R (TNFR)- exemplified liposomes. All the more critically, PR_bisR51-specific, where the same number of integrins tie to little RGD peptides. Along these lines, the proposed PR _b-focused on conveyance framework can possibly convey a helpful payload to prostate malignant growth cells in an efficient and specific way. (Demirgöz, Garg and Kokkoli, 2008)

Bauhinia purpura agglutinin (BPA) is a notable lectin that perceives galactosyl glycoproteins and glycolipids. In the present investigation, we firstly found that BPA bound to human prostate malignancy examples however not to typical prostate ones. In this way, we looked to create BPA-PEG-modified liposomes (BPA-PEG-LP) epitomizing anticancer medications for the treatment of prostate malignant growth. We analyzed the tumor targetability of BPA-PEG-LP with human prostate disease DU145 cells, and saw that fluorescently named BPA-PEG-LP overwhelmingly connected with the cells by means of the association between liposome-surface BPA and cell-surface galactosyl atoms.

We additionally saw that BPA-PEG-LP amassed in the prostate malignant growth tissue after the IV infusion to DU145 strong disease bearing mice, and unequivocally bound to the malignancy cells. In a remedial report, DU145 strong malignancy bearing mice were I.V infused thrice with BPA-PEG-LP epitomizing doxorubicin (BPA-PEG-LPDOX, 2 mg⁄kg⁄day as the DOX measurement) or PEG-modified liposomes embodying DOX (PEGLPDOX). Accordingly, BPA-PEG-LPDOX significantly stifled the development of the DU145 malignant growth cells, while PEG-LPDOX at similar measurements as DOX indicated minimal enemy of disease impact. The present examination proposed that BPA-PEG-LP could be a helpful medication transporter for the treatment of human prostate tumors (Ikemoto et al., 2016).

Targeted delivery of small-molecule drugs has the potential to enhance selective killing of tumor cells. We have identified previously an internalizing single chain [single chain variable fragment (scFv)] antibody that targets prostate cancer cells and identified the target antigen as CD166. We report here the development of immunoliposomes using this anti-CD166 scFv (H3). We studied the effects of a panel of intracellularly delivered, anti-CD166 immunoliposomal small-molecule drugs on prostate cancer cells. Immunoliposomal formulations of topotecan, vinorelbine, and doxorubicin each showed efficient and targeted uptake by three prostate cancer cell lines (Du-145, PC3, and LNCaP).

H3-immunoliposomal topotecan was the most effective in cytotoxicity assays on all three tumor cell lines, showing improved cytotoxic activity compared with non-targeted liposomal topotecan. Other drugs such as liposomal doxorubicin were highly effective against LNCaP but not PC3 or Du-145 cells, despite efficient intracellular delivery. Post-internalization events thus modulate the overall efficacy of intracellularly delivered liposomal drugs, contributing in some cases to the lower than expected activity in a cell line–dependent manner. Further studies on intracellular tracking of endocytosed liposomal drugs will help identify and overcome the barriers limiting the potency of liposomal drugs (Roth *et al.*, 2007)

Celastrol, a natural compound derived from the herb Tripterygium wilfordii, is known to have anticancer activity, but is not soluble in water. Objective: Formation of celastrol liposomes, to avoid the use of toxic solubilizing agents. Two different formulations of PEGylated celastrol liposomes were fabricated. Liposomal characteristics and serum stability were determined using dynamic light scattering. Drug entrapment efficacy and drug release were measured spectrophotometrically. Cellular internalization and anticancer activity was measured in prostate cancer cells. Liposomal celastrol displayed efficient serum stability, cellular internalization and anticancer activity, comparable to that of the free drug reconstituted in dimethyl sulfoxide. Discussion and conclusion: Liposomal celastrol can decrease the viability of prostate cancer cells, while eliminating the need for toxic solubilizing agents (Wolfram *et al.*, 2014).

To minimize the systemic toxicity prevalent to chemotherapeutics, we designed a novel
anticancer drug-encapsulating liposome conjugated with an RNA aptamer specific to the Prostate specific membrane antigen (PSMA), which is expressed on the surface of prostate Cancer cells. The RNA aptamer-conjugated liposome, termed an aptamosome, was prepared by the post-insertion method, in which RNA aptamer-conjugated micelles were inserted into liposome. These nanosized (90–

100 nm) aptamer-conjugated liposomes specifically bind to LNCa prostate epithelial cells that express PSMA and thus cause the nanoparticles to have
significantly enhanced in vitro cellular binding and uptake as compared with nontargeted
nanoparticles that lack the PSMA aptamer. Aptamosomes encapsulated with the anticancer
drug doxorubicin (Dox) were significantly more toxic to the targeted LNCaP cells than to
Nontargeted cancer cells. Dox-encapsulating aptamosomes administered to LNCaP xenograft
Nude mice were selectively retained in tumor tissue. We also demonstrated in vivo anticancer efficacy of the Dox-encapsulating PSMA-aptamosomes on tumor size regression in LNCaP
xenografts mice. We suggest that the encapsulation of toxic chemicals with aptamer
Conjugated liposomes will enable the use of these bio conjugates in clinical practice with
fewer side effects (Baek *et al.*, 2014).

Neovascular targeting is an established approach for the therapy of prostate cancer (PCa). Cationic liposomes have been shown to be absorbed by immature vascular endothelial cells due to negative electric charge of their outer cell membrane. We aimed to evaluate the antitumoural efficacy of paclitaxel encapsulated in cationic liposomes for the treatment of PCa. Tumors were generated by subcutaneous injection of 106 MatLu tumors cells into the right hind leg of 21 male Copenhagen rats. After tumor growth, the animals were treated by an IV infusion with either 5% glucose (Gl), paclitaxel (Pax), cationic liposomes (CL) or paclitaxel encapsulated in cationic liposomes (EndoTAG-1) on days 12, 14, 16 and 19.

Treatment was initiated on day 12 after tumor inoculation at mean tumors volumes of 0.31±0.13 mm3. On the last day of treatment, animals treated with EndoTAG-1 had the significantly lowest tumor volumes with 2.49±0.84 cm3 vs. Pax (5.59±0.45 cm3) vs. CL (3.87±1.25 cm3) vs. GL (5.17±1.70 cm3). The quantification of MVD showed the lowest count for EndoTAG-1treated tumors (11.78±2.68 vessels/mm2) followed by Gl (15.64±6.68 vessels/mm3), Pax (18.22± 9.50 vessels/mm3) and CL (40.9±32.8 vessels/mm3). The data confirm that neovascular targeting with EndoTAG-1 is a promising new method for the treatment of PCa by reducing the primary tumors mass and demonstrating benefits in the suppression of angiogenesis in comparison with the conventional treatment (Bode *et al.*, 2009).The inflammatory tumor microenvironment, and more specifically the

tumor-associated macrophages, plays an essential role in the development and progression of prostate cancer towards metastatic bone disease. Tumors are often characterized by a leaky vasculature, which - combined with the prolonged circulation kinetics of liposomes - leads to efficient tumor localization of these drug carriers, via the so-called enhanced permeability and retention (EPR) -effect. In this study, we evaluated the utility of targeted, liposomal drug delivery of the glucocorticoid dexamethasone in a model of prostate cancer bone metastases. Tumor-bearing Balb-c nu/nu mice were treated intravenously with 0.2–1.0–5.0mg/kg/week free- and liposomal DEX for 3–4 weeks and tumor growth was monitored by bioluminescent imaging. Intravenously administered liposomes localize efficiently to bone metastases in vivo and treatment of established bone metastases with (liposomal) dexamethasone resulted in a significant inhibition of tumor growth up to 26 days after initiation of treatment. Furthermore, 1.0mg/kg liposomal dexamethasone significantly outperformed 1.0mg/kg free dexamethasone, and was found to be well-tolerated at clinically-relevant dosages that display potent anti-tumor efficacy. Liposomal delivery of the glucocorticoid dexamethasone inhibits the growth of malignant bone lesions. We believe that liposomal encapsulation of dexamethasone offers a promising new treatment option for advanced, metastatic prostate cancer which supports further clinical evaluation (Kroon *et al.*, 2015).

CONCLUSION:

The new innovations in pharmacotherapy are very important to provide the maximum benefit of drugs given to the patients. So it is need of hour to promote the manufacturing of drugs for the diseases like cancer to provide the drug at the cellular level and increase the bioavailability of drugs for destruction of cancerous cells and avoid destroying of the normal healthy cells. The targeted drug delivery like nanoparticles (liposomes) is more beneficial to prevent the adverse effects the patients receive by getting the treatment of the diseases like cancer which is conventional in nature and destroy the healthy cells of body. This system of drug delivery must be used on broad range to avoid the expenses of conventional treatment.

Conflict of interest:

There is no conflict of interest.

Acknowledgment:

None

References

- Alaarg, A. *et al.* (2016) 'Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: An in vitro assessment', *International Journal of Nanomedicine*, 11, pp. 5027–5040. doi: 10.2147/IJN.S115995.
- Anabousi, S. *et al.* (2006) 'In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer', *European Journal of Pharmaceutical Sciences*. doi: 10.1016/j.ejps.2006.07.004.
- Antony, A. C. (1992) 'The biological chemistry of folate receptors', *Blood*, 79(11), pp. 2807–2820.
- Awad, N. S. *et al.* (2019) 'Ultrasonically controlled albumin-conjugated liposomes for breast cancer therapy', *Artificial Cells, Nanomedicine and Biotechnology*. Taylor & Francis, 47(1), pp. 705–714. doi: 10.1080/21691401.2019.1573175.
- Biswas, S. *et al.* (2013) 'Octa-arginine-modified pegylated liposomal doxorubicin: An effective treatment strategy for non-small cell lung cancer', *Cancer Letters*, 335(1), pp. 191–200. doi: 10.1016/j.canlet.2013.02.020.
- Boccalini, G. *et al.* (2017) 'Methylene blue-containing liposomes as new

photodynamic anti-bacterial agents', *Journal of Materials Chemistry B*. Royal Society of Chemistry, 5(15), pp. 2788–2797. doi: 10.1039/c6tb03367a.

- Cao, M. *et al.* (2019) 'Development of β-elemene and Cisplatin Co-Loaded Liposomes for Effective Lung Cancer Therapy and Evaluation in Patient-Derived Tumor Xenografts', *Pharmaceutical Research*. Springer New York LLC, 36(8). doi: 10.1007/s11095-019-2656-x.
- Cao, Y. *et al.* (1998) 'Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases', *Journal of Clinical Investigation*, 101(5), pp. 1055–1063. doi: 10.1172/JCI1558.
- Chen, Q. *et al.* (1999) 'Advances in Brief Liposomes Complexed to Plasmids Encoding Angiostatin and Endostatin Inhibit Breast Cancer in Nude Mice 1', pp. 3308–3312.
- Cheng, L. *et al.* (2014) 'GEII-modified liposomes for non-small cell lung cancer targeting: Preparation, ex vitro and in vivo evaluation', *International Journal of Nanomedicine*, 9(1), pp. 921–935. doi: 10.2147/IJN.S53310.
- Van Citters, G. W. and Lin, H. C. (1999) 'The ileal brake: a fifteen-year progress report.', *Current gastroenterology reports*, 1(5), pp. 404–409. doi: 10.1007/s11894-999-0022-6.
- Clarke, M. *et al.* (1998) 'Polychemotherapy for early breast cancer: An overview of the randomised trials', *Lancet*, 352(9132), pp. 930–942. doi: 10.1016/S0140-6736(98)03301-7.
- Dahan, A. and Hoffman, A. (2008) 'Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs', *Journal of Controlled Release*, 129(1), pp. 1–10. doi: 10.1016/j.jconrel.2008.03.021.
- Demirgöz, D., Garg, A. and Kokkoli, E. (2008) 'PR-b-targeted PEGylated liposomes for prostate cancer therapy', *Langmuir*, 24(23), pp. 13518–13524. doi: 10.1021/la801961r.
- Elwood, P. C. *et al.* (1986) 'The isolation, characterization, and comparison of the membrane-associated and soluble folate-binding proteins from human KB cells', *Journal of Biological Chemistry*, 261(33), pp. 15416–15423.
- Fleisher, D. *et al.* (1999) 'Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications', *Clinical Pharmacokinetics*, 36(3), pp. 233–254. doi: 10.2165/00003088-199936030-00004.
- Goldman, C. K. *et al.* (1998) 'Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate', *Proceedings of the National Academy of*

Sciences of the United States of America, 95(15), pp. 8795–8800. doi: 10.1073/pnas.95.15.8795.

- H.D., W. *et al.* (2013) 'Strategies to address low drug solubility in discovery and development', *Pharmacological Reviews*.
- Ikemoto, K. *et al.* (2016) 'human prostate cancer treatment', 107(1). doi: 10.1111/cas.12839.
- J.-A.W., C. *et al.* (2008) 'Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer', *Journal of the National Cancer Institute*.
- Jannin, V., Musakhanian, J. and Marchaud, D. (2008) 'Approaches for the development of solid and semi-solid lipid-based formulations', *Advanced Drug Delivery Reviews*, 60(6), pp. 734–746. doi: 10.1016/j.addr.2007.09.006.
- Jose, A. *et al.* (2019) *Temperature-sensitive liposomes for co-delivery of tamoxifen and imatinib for synergistic breast cancer treatment*, *Journal of Liposome Research*. Taylor & Francis. doi: 10.1080/08982104.2018.1502315.
- Kaufmann, M. *et al.* (2000) 'Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial', *Journal of Clinical Oncology*, 18(7), pp. 1399–1411. doi: 10.1200/JCO.2000.18.7.1399.
- Keller, A. M. *et al.* (2004) 'Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer', *Journal of Clinical Oncology*, 22(19), pp. 3893–3901. doi: 10.1200/JCO.2004.08.157.
- Kim, M. W., Niidome, T. and Lee, R. (2019) 'Glycol Chitosan-Docosahexaenoic Acid Liposomes for Drug Delivery: Synergistic Effect of Doxorubicin-Rapamycin in Drug-Resistant Breast Cancer', *Marine drugs*, 17(10). doi: 10.3390/md17100581.
- Klijn, J. G. M. *et al.* (2000) 'Combined Treatment With Buserelin and Tamoxifen in', *Cancer*, 92(11).
- Kumar, P., Huo, P. and Liu, B. (2019) 'Formulation Strategies for Folate-Targeted Liposomes and Their Biomedical Applications', *Pharmaceutics*, 11(8), p. 381. doi: 10.3390/pharmaceutics11080381.
- Li, L., An, X. and Yan, X. (2015) 'Folate-polydiacetylene-liposome for tumor targeted drug delivery and fluorescent tracing', *Colloids and Surfaces B: Biointerfaces*, 134, pp. 235–239. doi: 10.1016/j.colsurfb.2015.07.008.
- Li, R. *et al.* (2011) 'All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells', *Journal of*

Controlled Release. Elsevier B.V., 149(3), pp. 281–291. doi: 10.1016/j.jconrel.2010.10.019.

- Li, X. M. *et al.* (2009) 'Targeted delivery of doxorubicin using stealth liposomes modified with transferrin', *International Journal of Pharmaceutics*, 373(1–2), pp. 116–123. doi: 10.1016/j.ijpharm.2009.01.023.
- Lin, C. *et al.* (2018) 'Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide', *Drug Delivery*. Taylor and Francis Ltd, 25(1), pp. 256–266. doi: 10.1080/10717544.2018.1425777.
- Liu, L. H. *et al.* (2017) 'Dual-Stage Light Amplified Photodynamic Therapy against Hypoxic Tumor Based on an O2 Self-Sufficient Nanoplatform', *Small*, 13(37), pp. 1–9. doi: 10.1002/smll.201701621.
- Liu, Y. *et al.* (2008) 'A potential target associated with both cancer and cancer stem cells : A combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes', 129, pp. 18–25. doi: 10.1016/j.jconrel.2008.03.022.
- 'Manoj M.Nerurkar' (no date).
- Marengo, A. *et al.* (2019) 'Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate-copper complex loaded into hyaluronic acid decorated liposomes', *Biochimica et Biophysica Acta - General Subjects*. Elsevier B.V, 1863(1), pp. 61–72. doi: 10.1016/j.bbagen.2018.09.018.
- Martins, D. B. *et al.* (2011) 'Cholinergic system of rats treated with vincristine sulphate and nandrolone decanoate', *Comparative Clinical Pathology*, 20(1), pp. 33–37. doi: 10.1007/s00580-009-0948-y.
- Merisko-Liversidge, E. M. and Liversidge, G. G. (2008) 'Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds', *Toxicologic Pathology*, 36(1), pp. 43–48. doi: 10.1177/0192623307310946.
- Mrugala, M. M. *et al.* (2019) 'Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer', *Clinical Breast Cancer*. Elsevier Inc. doi: 10.1016/j.clbc.2019.04.004.
- Nguyen, V. Du *et al.* (2016) 'Active tumor-therapeutic liposomal bacteriobot combining a drug (paclitaxel)-encapsulated liposome with targeting bacteria (Salmonella Typhimurium)', *Sensors and Actuators, B: Chemical*. Elsevier B.V., 224, pp. 217–224. doi: 10.1016/j.snb.2015.09.034.
- O'Reilly, M. S. *et al.* (1994) 'Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma', *Cell*, 79(2), pp. 315–328. doi: 10.1016/0092-8674(94)90200-3.
- O'Shaughnessy, J. A. (2003) 'Pegylated liposomal doxorubicin in the

treatment of breast cancer', *Clinical Breast Cancer*. Elsevier Inc., 4(5), pp. 318–328. doi: 10.3816/CBC.2003.n.037.

- Ou, Y. C. *et al.* (2016) 'Gold Nanoantenna-Mediated Photothermal Drug Delivery from Thermosensitive Liposomes in Breast Cancer', *ACS Omega*, 1(2), pp. 234–243. doi: 10.1021/acsomega.6b00079.
- Palchetti, S. *et al.* (2019) 'Effect of Glucose on Liposome–Plasma Protein Interactions: Relevance for the Physiological Response of Clinically Approved Liposomal Formulations', *Advanced Biosystems*, 3(2), pp. 1–11. doi: 10.1002/adbi.201800221.
- Pérez-Herrero, E. and Fernández-Medarde, A. (2015) 'Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy', *European Journal of Pharmaceutics and Biopharmaceutics*, 93(March), pp. 52–79. doi: 10.1016/j.ejpb.2015.03.018.
- Porter, C. J. H. and Charman, W. N. (2001) 'In vitro assessment of oral lipid based formulations', *Advanced Drug Delivery Reviews*, 50(SUPPL. 1), pp. 127–147. doi: 10.1016/S0169-409X(01)00182-X.
- Pouton, C. W. (2006) 'Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system', *European Journal of Pharmaceutical Sciences*, 29(3-4 SPEC. ISS.), pp. 278–287. doi: 10.1016/j.ejps.2006.04.016.
- Prabhu, S., Ortega, M. and Ma, C. (2005) 'Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam', *International Journal of Pharmaceutics*, 301(1–2), pp. 209–216. doi: 10.1016/j.ijpharm.2005.05.032.
- Rodallec, A. *et al.* (2018) 'Docetaxel–trastuzumab stealth immunoliposome: Development and in vitro proof of concept studies in breast cancer', *International Journal of Nanomedicine*, 13, pp. 3451–3465. doi: 10.2147/IJN.S162454.
- Roger, E., Lagarce, F. and Benoit, J. P. (2011) 'Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration', *European Journal of Pharmaceutics and Biopharmaceutics*. Elsevier B.V., 79(1), pp. 181–188. doi: 10.1016/j.ejpb.2011.01.021.
- Samson, A. A. S. *et al.* (2019) 'Liposomal co-delivery-based quantitative evaluation of chemosensitivity enhancement in breast cancer stem cells by knockdown of GRP78/CLU', *Journal of Liposome Research*. Taylor & Francis, 29(1), pp. 44–52. doi: 10.1080/08982104.2017.1420081.
- Seitz, H. *et al.* (2005) 'Three-dimensional printing of porous ceramic scaffolds for bone tissue engineering', *Journal of Biomedical Materials Research - Part B Applied Biomaterials*. doi: 10.1002/jbm.b.30291.
- Stover, T. and Kester, M. (2003) 'Liposomal Delivery Enhances Short-

Chain Ceramide-Induced Apoptosis of Breast Cancer Cells', *Journal of Pharmacology and Experimental Therapeutics*, 307(2), pp. 468–475. doi: 10.1124/jpet.103.054056.

- Swenson, S. *et al.* (2004) 'Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression', *Molecular Cancer Therapeutics*, 3(4), pp. 499–511.
- Torchilin, V. (2008) 'Antibody-modified liposomes for cancer chemotherapy', *Expert Opinion on Drug Delivery*. doi: 10.1517/17425247.5.9.1003.
- Usuda, J. *et al.* (2007) 'Photodynamic therapy for lung cancers based on novel photodynamic diagnosis using talaporfin sodium (NPe6) and autofluorescence bronchoscopy', *Lung Cancer*, 58(3), pp. 317–323. doi: 10.1016/j.lungcan.2007.06.026.
- Wang, X. *et al.* (2019) 'Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with pfv for the treatment of non-smallcell lung cancer', *International Journal of Nanomedicine*. Dove Medical Press Ltd., 14, pp. 4071–4090. doi: 10.2147/IJN.S194304.
- Xing, H., Hwang, K. and Lu, Y. (2016) 'Recent developments of liposomes as nanocarriers for theranostic applications', *Theranostics*, 6(9), pp. 1336–1352. doi: 10.7150/thno.15464.
- Yang, Y. *et al.* (2019) 'Near-infrared light triggered liposomes combining photodynamic and chemotherapy for synergistic breast tumor therapy', *Colloids and Surfaces B: Biointerfaces*. Elsevier B.V., 173, pp. 564–570. doi: 10.1016/j.colsurfb.2018.10.019.
- Zhang, M. *et al.* (2019) 'Liposome mediated-CYP1A1 gene silencing nanomedicine prepared using lipid film-coated proliposomes as a potential treatment strategy of lung cancer', *International Journal of Pharmaceutics*. doi: 10.1016/j.ijpharm.2019.04.078.